About VaxGen
VaxGen is a publicly listed company based in San Francisco (United States) founded in 1995. Late clinical stage company developing vaccine for HIVAIDS. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its legal entity is VaxGen, Inc. Similar companies include Moderna, Adaptive Biotechnologies and Generate Biomedicines; 3 of its 3 listed similar companies have raised funding.
Company details
VaxGen develops vaccines for HIVAIDS. AIDSVAX is the trade name for all formulations of VaxGens preventive HIVAIDS vaccine. AIDSVAX, is in Phase III clinical trials (as of Mar 2016), and is meant to prevent HIV infection in people who have not been exposed to the virus. AIDSVAX is made of synthetic proteins cloned from gp120 and contains no genetic material. This ensures that AIDSVAX remains incapable of causing HIV or AIDS. The company sold its Anthrax vaccine to rival Emergent BioSolutions in 2008. The company owns a biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that could be used to make cell culture or microbial biologic products. The company acquired diaDexus in April 2010 for 28M.
- Headquarters San Francisco, United States
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website vaxgen.com
- Social LinkedIn
- Legal Name Vaxgen, Inc.
- Latest Funding Round$5.19M (USD), Post-IPO
Aug 2010
Funding Insights of VaxGen
- Total Rounds 1
- Last Round Post-IPO — $5.19M
- First Round $5.19M
(Aug 2010)
All 1 funding rounds of VaxGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2010 | $5.19M | Post-IPO | – | – | – |
Timeline of VaxGen
2 dated milestones of VaxGen across 15 years, from founding to its latest funding, stage changes and deals.
- Founded VaxGen is founded.
- Funding First funding round of $5.2M.
Similar companies to VaxGen
VaxGen has 3 listed similar companies in our database, 3 of them funded. They include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| generatebiomedicines.com | 2018 | Somerville, United States | $643M | 286 | Developer of novel protein-based therapeutics using machine learning and biological engineering |
Detailed similar companies of VaxGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of VaxGen
Websites that share an audience with VaxGen (vaxgen.com).
Websites whose visitors overlap most with VaxGen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
gskvaccines.com | gskvaccines.com | 100% | – | ||
| crucell.com | 100% | View details | |||
cytrx.com | cytrx.com | 100% | – | ||
sanofipasteur.com | sanofipasteur.com | 100% | – | ||
| genphar.com | 100% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for VaxGen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as VaxGen (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about VaxGen
VaxGen was founded in 1995 and raised its 1st funding round 15 years after it was founded.
VaxGen is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
VaxGen develops vaccines for HIVAIDS. AIDSVAX is the trade name for all formulations of VaxGens preventive HIVAIDS vaccine. AIDSVAX, is in Phase III clinical trials (as of Mar 2016), and is meant to prevent HIV infection in people who have not been exposed to the virus. AIDSVAX is made of synthetic proteins cloned from gp120 and contains no genetic material. This ensures that AIDSVAX remains incapable of causing HIV or AIDS. The company sold its Anthrax vaccine to rival Emergent BioSolutions in 2008. The company owns a biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that could be used to make cell culture or microbial biologic products. The company acquired diaDexus in April 2010 for 28M.
VaxGen's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
VaxGen operates through Vaxgen, Inc..